Drug Trial Radar · NCT06576843
INDV-6001 Multiple-Dose Pharmacokinetic Study
Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
Sep 17, 2024
Primary completion
Jan 21, 2026
Study completion Jan 21, 2026
Sponsor
- Lead sponsor
- Indivior Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre, open-label, multiple dose study of INDV-6001 in adult participants with moderate or severe OUD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). The current study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD to select optimum dosing regimens for future studies. Prior to receiving INDV-6001, participants will be stabilised on 12-16 mg of transmucosal (TM) BUP (SUBOXONE®) or will transition from a 100-mg monthly maintenance dose of SC extended-release BUP (SUBLOCADE®). This study will also evaluate the use of alternative injection sites (thigh, back of upper arm), which may be desirable in this patient population for the anticipated extended durations of treatment.
Conditions
- Moderate to Severe Opioid Use Disorder
Interventions
INDV-6001Drug
Extended-release subcutaneous injection
SuboxoneDrug
Oral sublingual film
SublocadeDrug
Extended-release subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Steady-state area under the plasma concentration-time curve over the dosing interval (AUCtau) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
- Steady-state maximum observed plasma concentration (Cmax) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
- Steady-state time to attain the maximum observed plasma concentration (Tmax) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
- Steady-state minimum plasma concentration over a dosing interval (Cmin) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
- Steady-state plasma concentration measured at the end of the dosing interval (Ctrough) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
- Steady-state average plasma concentration over the dosing interval (Cavg) of buprenorphine following INDV-6001 injection in the abdomenTime frame: Up to 260 days
- Steady-state ratio of peak to trough plasma concentrations over a dosing interval (% fluctuation) of buprenorphine following INDV-6001 injectionTime frame: Up to 260 days
- Steady-state area under the plasma concentration-time curve over the dosing interval (AUCtau) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
- Steady-state maximum observed plasma concentration (Cmax) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
- Steady-state time to attain the maximum observed plasma concentration (Tmax) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
- Steady-state minimum plasma concentration over a dosing interval (Cmin) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
- Steady-state plasma concentration measured at the end of the dosing interval (Ctrough) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
- Steady-state average plasma concentration over the dosing interval (Cavg) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
- Steady-state ratio of peak to trough plasma concentrations over a dosing interval (% fluctuation) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection locationTime frame: Up to 168 days [24 weeks]
- Steady-state area under the plasma concentration-time curve over the dosing interval (AUCtau) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
- Steady-state maximum observed plasma concentration (Cmax) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
- Steady-state time to attain the maximum observed plasma concentration (Tmax) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
- Steady-state minimum plasma concentration over a dosing interval (Cmin) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
- Steady-state plasma concentration measured at the end of the dosing interval (Ctrough) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
- Steady-state average plasma concentration over the dosing interval (Cavg) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
- Steady-state ratio of peak to trough plasma concentrations over a dosing interval (% fluctuation) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection locationTime frame: Up to 128 days [16 weeks]
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Artemis Institute for Clinical Research
San Diego, California
Innovative Clinical Research, Inc.
Miami Lakes, Florida
Chicago Clinical Research Institute Inc.
Chicago, Illinois
Precise Research Centers
Flowood, Mississippi
Hassman Research Institute (Cenexel HRI - Marlton)
Marlton, New Jersey
Richmond Behavioral Associates
Staten Island, New York
Midwest Clinical Research
Dayton, Ohio
Insite Clinical Research, LLC
DeSoto, Texas
Memorial Hermann Village
Houston, Texas
Pillar Clinical Research
Richardson, Texas
Progressive Clinical Research
Bountiful, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.